NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
Eli Lilly and Company
NYU Langone Health